Losartan inhibits renal sympathetic nerve activity in Paraventricular nucleus in chronic heart failure rat

Abstract

Abstract: AIM: Left coronary artery ligation (LAD) was used to induce heart failure.Losartan was microinjected into paraventricular nucleus (PVN ), heart rate(HR), blood pressure(BP) and renal sympathetic nerve activity (RSNA) were measured.The mechanism of PVN in chronic heart failure was investigated. METHODS: Sprague-Dawley male rats were selected for LAD ligation for heart failure models, the variation of cardiac function was detected by echocardiography.Losartan was microinjected into PVN, the responses of HR, BP and RSNA were analyzed. RESULTS: Compared with sham group, the level of LV was increased (P <0.01), the levels of EF and FS were decreased in operation group (P <0.01, P < 0.05).The level of RSNA was decreased greater in operation group than that in sham group(P <0.05). CONCLUSION: Losartan microinjection into PVN can decrease the level of RSNA in chronic heart failure.

Key words: heart failure, paraventricular nucleus, losartan, renal sympathetic nerve activity

CLC Number:

R541.6

GUI Le, ZHU Jian-hua, CHEN Qing-hui. Losartan inhibits renal sympathetic nerve activity in Paraventricular nucleus in chronic heart failure rat[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(11): 1212-1215.

References

[1] Liu D, Gao L, Roy SK, et al.Neuronal angiotensin II type 1 receptor upregulation in heart failure:activation of activator protein 1 and Jun N-terminal kinase[J].Circ Res, 2006, 99(9):1004-1011.
[2] Davidoff AW, Boyden PA, Schwartz K, et al.Congestive heart failure after myocardial infarction in the rat:cardiac force and spontaneous sarcomere activity[J].Ann N Y Acad Sci, 2004, 1015(5):84-95.
[3] Zucker IH, Hackley JF, Cornish KG, et al.Chronic baroreceptor activation enhances survival in dogs with pacing- induced heart failure[J].Hypertension, 2007, 50(5):904-910.
[4] Zoccali C, Mallamaci F, Parlongo S, et al.Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease[J].Circulation, 2002, 105(11):1354-1359.
[5] 王安才, 赵振东.血管紧张素Ⅱ Ⅰ 型受体拮抗剂的应用前景[J].中国临床药理学与治疗学, 2001, 6(1):94-96.
[6] Ferguson AV, Latchford KJ.Local circuitry regulates the excitability of rat neurohypophysial neurons[J].Exp Physiol, 2000, 85(3):153S-161S.
[7] Cato MJ, Toney GM.Angiotensin II excites paraventricular nucleus neurons that innervate the rostral ventrolateral medulla:an in vitro patch-clamp study in brain slices[J]. J Neurophysiol, 2005, 93(1):403-413.
[8] Richard D, Bourque CW.Synaptic control of rat supraoptic neurones during osmotic stimulation of the organum vasculosum lamina terminalis in vitro[J].J Physiol(Lond), 1995, 489(Pt 2):567-577.
[9] Li DP, Pan HL.Plasticity of GABAergic control of hypothalamic presympathetic neurons in hypertension[J].Am J Physiol Heart Circ Physiol, 2006, 290(3):H1110-1119.
[10] Li Y, Zhang W, Stern JE.Nitric oxide inhibits the firing activity of hypothalamic paraventricular neurons that innervate the medulla oblongata:role of GABA[J].Neuroscience, 2003, 118(3):585-601.
[11] Sonner PM, Stern JE.Functional role of A-type potassium currents in rat presympathetic PVN neurones[J].J Physiol, 2007, 582(Pt 3):1219-1238.
[12] Li DP, Pan HL.Role of gamma-aminobutyric acid (GABA) A and GABAB receptors in paraventricular nucleus in control of sympathetic vasomotor tone in hypertension[J]. J Pharmacol Exp Ther, 2007, 320(2):615-626.
[13] Wang RJ, Zeng QH, Wang WZ, et al.GABA(A) and GABA(B) receptor-mediated inhibition of sympathetic outflow in the paraventricular nucleus is blunted in chronic heart failure[J].Clin Exp Pharmacol Physiol, 2009, 36(5 6):516-522.
[14] Yoshimura R, Sato T, Kawada T, et al.Increased brain angiotensin receptor in rats with chronic high-output heart failure[J].J Card Fail, 2000, 6(1):66-72.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
[3]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[4]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[5]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[6]	LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.
[7]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[8]	CHEN Lifang, WANG Bo, WANG Weirong. Research advances of histone deacetylase 3 in cardiovascular diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.
[9]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[10]	SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang. Advances in drugs and genetic pharmacology for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.
[11]	WEI Zihan,LI Dongbo，YUAN Zheng,LU Ying, YANG Guojie. Clinical trial of sacubitril/valsartan in the treatment of Pulmonary hypertension (PH) due to left heart disease (LHD) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 57-62.
[12]	HUANG Ting, WANG Hegui. Research progress in regulation of heart failure by β-adrenergic-receptor-PKA-AKAP signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 592-596.
[13]	WANG Shibiao, WANG Chengyi, WENG Bin, GUO Xiaofeng, LIN Hai. Comparison of the efficacy of non-invasive USCOM and milrinone in children with severe pneumonia and heart failure and its effect on brain natriuretic peptide levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1402-1407.
[14]	LIU Yu, ZHANG Ying, WANG Ancai. Effect of rhBNP on chronic systolic heart failure combined with diuretic resistance and concentration of TNF-α and NPY [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 814-820.
[15]	WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.